LH-21

LH-21 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole) is a triazole-derived, peripherally restricted cannabinoid receptor 1 (CB1) antagonist and G-protein coupled receptor 55 (GPR55) agonist. Originally developed by the Spanish National Research Council (CSIC) and Fundación IMABIS, LH-21 was designed to overcome the central nervous system-mediated psychiatric side effects (such as anxiety and depression) associated with globally acting CB1 inverse agonists like rimonabant. Preclinical studies have demonstrated that LH-21 effectively reduces food intake and body weight gain in animal models of obesity. Additionally, LH-21 has been shown to improve glucose tolerance, enhance insulin sensitivity, and protect pancreatic beta-cells from apoptosis, partially through the direct activation of GPR55. It also exhibits anti-inflammatory and hepatoprotective properties, reducing liver damage in models of drug-induced liver injury.

Other names

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole611207-11-5